Custom Peptide Libraries 

With our proprietary parallel synthesis technology, Mimotopes can synthesise hundreds of peptides simultaneously, thereby massively reducing the price and time to delivery.

High quality Peptide Libraries at affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products.

Efficient & Economical Screening Solutions

Peptide Libraries have dozens of potential applications. From screening to epitope mapping, a peptide library can be exclusively designed to your specifications, for your research.

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for your free quote! 

Phone: +61 3 9565 1111
Fax: +61 3 9565 1199 
Email: mimotopes@mimotopes.com

Go to article: Home | EDS: Treating a medical zebraGo to article: Scandinavian Health LtdGo to article: EditorialGo to article: Emirates SkyCargoGo to article: ContentsGo to article: Nolato Company Insight Go to article: NolatoGo to article: NewsGo to article: The pharma industry briefingGo to article: Subcuject Company Insight Go to article: SubcujectGo to article: Horizon 2020: a look back at flagship EU pharma projectsGo to article: SanofiGo to article: Sky high: should US drug prices fall in-line with the rest of the world?Go to article: Nipro PharmapackagingGo to article: Q&A: talking drug quality with Valisure, the first analytical pharmacyGo to article: NemeraGo to article: What does ‘ageing’ mean when it comes to drug development? Go to article: Swiss WorldCargoGo to article: Manufacturing medicines in space: how astronauts will make their own drugs Go to article: MimotopesGo to article: Aducanumab’s surprising revival: how an Alzheimer’s drug came back from the deadGo to article: Molnar Company Insight Go to article: Molnar-InstituteGo to article: Ehlers-Danlos syndrome: The zebra in the roomGo to article: KugelmeiersGo to article: Stop ignoring the two billion: pharma’s role in expanding access to medicineGo to article: SkyepharmaGo to article: IDMP: turning attention to patient benefitsGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: EventsGo to article: Next issue